Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q13461

UPID:
FOXE3_HUMAN

ALTERNATIVE NAMES:
Forkhead-related protein FKHL12; Forkhead-related transcription factor 8

ALTERNATIVE UPACC:
Q13461; Q5SVY9; Q9NQV9

BACKGROUND:
The Forkhead box protein E3, with alternative names Forkhead-related protein FKHL12 and Forkhead-related transcription factor 8, is a transcription factor essential for controlling lens epithelial cell dynamics, including their growth, apoptosis, and the cell cycle. It plays a critical role during lens development by managing the balance between lens fiber cells and anterior lens epithelium cells, facilitating lens vesicle closure, and is key in the development of the eye's anterior segment through regulation of DNAJB1 expression.

THERAPEUTIC SIGNIFICANCE:
Forkhead box protein E3's involvement in diseases such as anterior segment dysgenesis 2, cataract 34, multiple types, and familial thoracic aortic aneurysm 11 highlights its potential as a therapeutic target. Exploring its function further could lead to innovative treatments for these eye and vascular diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.